ALS Center Leuven

UZ Leuven

The Leuven ALS center combines the diagnosis and multidisciplinary care for ALS and ALS/FTD (frontotemporal dementia) patients with clinical and basic research activities.

UZLeuven
UZ Leuven

Our clinical research activities include genetic, imaging (such as PET/MRI), electrophysiological and biomarker studies, as well as phase I-III clinical trials. Our basic research focuses on the generation of patient-derived stem cell models for ALS and FTD to study disease mechanisms. We also use these models to identify and validate molecular targets for new treatments.

Contact
Location
Herestraat 49, 3000 Leuven, Belgium

Our Specialists

Philip van Damme

Professor of Neurology

Philip van Damme studied neurology at KU Leuven medical school. During his […]

Philip van Damme
Current trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Active
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more